Join our Mailing List 
Home > Articles
Articles
CYP4F2 genetic variant alters required warfarin dose
The discovery of a new genetic marker for warfarin dosage has just been described in the peer-reviewed journal, Blood Online, in an article entitled “CYP4F2 genetic variant alters required warfarin dose.” The discovery was made by a group at the Marshfield Clinic Research Foundation led by Michael D. Caldwell, M.D., Ph.D. This marker, which causes a single amino acid change (valine 433 to methionine) in the CYP4F2 enzyme, was found to be associated with clinically-significant differences in warfarin dosage in three independent patient groups stabilized on warfarin (n=1054) recruited by the Marshfield Clinic, University of Florida and Washington University.
Dr. Caldwell is the founding director of the Marshfield Clinic's Personalized Medicine Research Program, and the organizer of the International Warfarin Pharmacogenetics Consortium, a group consisting of researchers from 21 institutions in the U.S. and 8 foreign countries that is pooling data to establish a consensus model for warfarin dosing.
In November, 2007, Osmetech PLC announced the exclusive licensing of the new Marshfield warfarin marker, with rights to sublicense.